Vanda Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VNDA research report →
About the company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia.
- CEO
- Mihael H. Polymeropoulos
- IPO
- 2006
- Employees
- 368
- HQ
- Washington, DC, US
Price Chart
- Market Cap
- $373.44M
- P/E
- -1.53
- P/S
- 1.71
- P/B
- 1.32
- EV/EBITDA
- -2.44
- Div Yield
- 0.00%
- Gross Margin
- 92.46%
- Op Margin
- -73.64%
- Net Margin
- -109.99%
- ROE
- -61.41%
- ROIC
- -52.76%
- Revenue
- $216.10M · 8.72%
- Net Income
- $-220,474,000 · -1066.53%
- EPS
- $-3.74 · -1068.75%
- Op Income
- $-151,168,000
- FCF YoY
- -579.76%
- 52W High
- $9.94
- 52W Low
- $4.14
- 50D MA
- $6.34
- 200D MA
- $6.46
- Beta
- 0.60
- Avg Volume
- 1.05M
Get TickerSpark's AI analysis on VNDA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 4, 26 | McGuire Daniel Patrick | other | 80,000 |
| Jun 4, 26 | Chrousos Phaedra | other | 41,600 |
| Jun 4, 26 | Duncan Charles Cliff | other | 41,600 |
| Jun 4, 26 | DUGAN RICHARD W | other | 41,600 |
| Jun 4, 26 | Ward Anne Sempowski | other | 41,600 |
| Jun 4, 26 | Honore Tage | other | 41,600 |
| Jun 4, 26 | Mitchell Stephen Ray | other | 41,600 |
| Jun 4, 26 | McGuire Daniel Patrick | other | 0 |
| Jun 4, 26 | McGuire Daniel Patrick | other | 0 |
| Jun 4, 26 | McGuire Daniel Patrick | other | 0 |
Our VNDA coverage
Recent articles, reports, and earnings notes.
No research on VNDA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VNDA report →Similar companies
Peers in the same neighborhood.